Literature DB >> 18088240

Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme.

F-H Su1, J-D Chen, S-H Cheng, K-Y Sung, J-J Jeng, F-Y Chu.   

Abstract

Hepatitis B virus (HBV) infection and its sequelae remain a major health problem for Taiwan. The national hepatitis B (HB) vaccination programme was first launched in 1984 to combat the spread of this infection. This study examined the status of HBV infection amongst students at a Taiwanese university in 2005, 18 years after the implementation of a nation-wide mass HB vaccination programme. In 2005, 5875 new university entrants, who were born during the period 1 July 1976 to 30 June 1988, were subdivided into one of 12 one-year-interval birth-year cohorts. Each student was individually tested for serum hepatitis B surface antigen (HBsAg), Antibody to hepatitis B surface antigen (anti-HBs) and antibody to hepatitis B core antigen (anti-HBc) status. We observed a declining trend of past exposure to HB infection from 48.7% (1976 birth-year cohort) to 5.2% (1987 birth-year cohort). The prevalence of chronic HB infection also declined from 14.5% (1976 birth-year cohort) to 1.9% (1987 birth-year cohort). The prevalence of persistent HB immunity through (earlier) active vaccination declined from 72% (1984 birth-year cohort) to 41.6% (1987 birth-year cohort). The prevalence of HB infection-naïve individuals increased from 18.2% (1984 birth-year cohort) to 53.1% (1987 birth-year cohort). This study demonstrates that as the implementation of the mass HB vaccination programme in 1984, the incidence of HB infection in Taiwan has declined, although a 'waning-off' effect of serum anti-HBs to low or undetectable levels, which may not provide protection, amongst this student population has arisen, 18 years following the implementation of the nation-wide HB vaccination programme. Such a situation may mean that these individuals may not be effectively protected against future HB infection. A booster dose of HB vaccine, given 18 years following HB vaccination, perhaps even earlier, should be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18088240     DOI: 10.1111/j.1365-2893.2007.00890.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  16 in total

Review 1.  Hepatitis B immunization strategies: timing is everything.

Authors:  Christopher O Mackie; Jane A Buxton; Sayali Tadwalkar; David M Patrick
Journal:  CMAJ       Date:  2009-01-20       Impact factor: 8.262

2.  A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Authors:  Brenna C Simons; Philip R Spradling; Dana J T Bruden; Carolyn Zanis; Samantha Case; Tammy L Choromanski; Minjun Apodaca; Hazel D Brogdon; Gaelen Dwyer; Mary Snowball; Susan Negus; Michael G Bruce; Chihiro Morishima; Cindy Knall; Brian J McMahon
Journal:  J Infect Dis       Date:  2016-04-07       Impact factor: 5.226

Review 3.  Hepatitis B (prevention).

Authors:  Suzanne Norris; Abdul Mohsen
Journal:  BMJ Clin Evid       Date:  2009-09-23

4.  Long-term persistence of immunity after hepatitis B vaccination: Is this substantiated by the literature?

Authors:  Terence T Lao
Journal:  Hum Vaccin Immunother       Date:  2017-03-01       Impact factor: 3.452

5.  Relationship between age and prevalence of hepatitis B infection in first-year university students in Hong Kong.

Authors:  S S H Suen; T T Lao; O K Chan; T K Lau; T Y Leung; P K S Chan
Journal:  Infection       Date:  2012-12-12       Impact factor: 3.553

6.  Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico.

Authors:  María Elena Cárdenas-Perea; Eduardo Gómez-Conde; Gerardo Santos-López; Irma Pérez-Contreras; María Alicia Díaz-Orea; José Luís Gándara-Ramírez; Othón Rafael Cruz Y López; Luis Márquez-Domínguez; Francisca Sosa-Jurado
Journal:  Hum Vaccin Immunother       Date:  2016-05-12       Impact factor: 3.452

7.  Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma.

Authors:  Ming-Chu Chang; Chien-Hung Chen; Ja-Der Liang; Yu-Wen Tien; Chiun Hsu; Jau-Min Wong; Yu-Ting Chang
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

8.  Immune persistence after hepatitis B vaccination in infancy - Fact or fancy?

Authors:  Terence T Lao
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

9.  Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China.

Authors:  Hong Zhang; Qingmei Li; Jie Sun; Chunyan Wang; Qing Gu; Xiangwei Feng; Bing Du; Wei Wang; Xiaodong Shi; Siqi Zhang; Wanyu Li; Yanfang Jiang; Junyan Feng; Shumei He; Junqi Niu
Journal:  Int J Med Sci       Date:  2011-05-20       Impact factor: 3.738

10.  Impact of neonatal hepatitis B vaccination programme on age-specific prevalence of hepatitis B infection in teenage mothers in Hong Kong.

Authors:  T T Lao; D S Sahota; S S H Suen; P K S Chan; T Y Leung
Journal:  Epidemiol Infect       Date:  2012-12-05       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.